#1 Clinical Trials Search in Europe

Hodgkin’s disease – Trials in Disease

Go back

Ongoing Clinical Trials for Hodgkin’s Disease

This article provides detailed information about 27 ongoing clinical trials investigating new treatments for Hodgkin’s disease. These studies are being conducted across multiple countries in Europe and involve various treatment approaches including immunotherapy, targeted therapy, and chemotherapy combinations. (Also known as: Hodgkin lymphoma, Hodgkin’s lymphoma)

Clinical trial locations

Phase III Trial Comparing ABVD vs A2VD Treatment With PET-Guided Radiation Therapy for Patients With Early Stage Hodgkin Lymphoma

This trial is for patients with early stage Hodgkin lymphoma who have not received previous treatment. To be eligible, patients must be between 16 and 69 years old (or 18-69 in some centers) and have confirmed classical Hodgkin lymphoma at Stage I or II above the diaphragm without large chest tumors. Patients must have adequate bone marrow function, with neutrophils at least 1.0 x 109/l, platelets at least 100 x 109/l, and hemoglobin at least 8g/dl. They must be fit to receive anthracycline-based chemotherapy, with heart function of at least 50% if there is a history of heart disease. Kidney function should show creatinine clearance above 40 ml/min, and liver function tests must be within acceptable ranges.

Patients cannot participate if they have a different cancer type, are outside the specified age range, cannot follow study procedures, are pregnant or breastfeeding, or have participated in another trial recently. Those with certain medical conditions or unable to provide informed consent are also excluded.

The trial compares two chemotherapy regimens: standard ABVD and modified A2VD. Both treatments may be combined with radiation therapy based on PET scan results after initial treatment cycles. The study aims to determine if the modified regimen improves progression-free survival compared to standard treatment while monitoring side effects and long-term outcomes.

Investigational drugs: ABVD is a combination of four drugs that work together to stop cancer cells from growing and dividing. A2VD is another combination being studied to see if it can improve outcomes compared to traditional ABVD treatment. ISRT (involved-site radiation therapy) uses high-energy rays to target cancer cells in specific body areas and is often used with chemotherapy.

Study of Atezolizumab and Drug Combination for Patients with Relapsed or Refractory Hodgkin’s Lymphoma Eligible for Stem Cell Transplant

This trial tests a new treatment combination for Hodgkin’s lymphoma that has returned or not responded to initial treatments. Participants must be between 18 and 60 years old and have had only one previous treatment. They must be eligible for autologous stem cell transplant and have a performance status of 2 or less on the ECOG scale. Adequate blood function is required, including sufficient neutrophils, platelets, and hemoglobin, unless the bone marrow is affected by the disease.

Patients are excluded if they have a different cancer type, are outside the age range, are part of a vulnerable population, cannot follow study procedures, have conditions that make participation unsafe, are in another trial, recently had major surgery, have severe allergic reactions to study medications, are pregnant or breastfeeding, or have active infections or uncontrolled organ diseases.

The trial is divided into two phases. Phase I determines the safest dose of atezolizumab when combined with the BEGEV regimen (bendamustine hydrochloride, gemcitabine, vinorelbine). Phase II assesses how well this combination works before stem-cell transplantation. The study monitors response to therapy and any side effects over several treatment cycles.

Investigational drugs: Atezolizumab is immunotherapy that helps the immune system attack cancer cells by blocking a protein that prevents immune response. The BEGEV regimen is a combination of chemotherapy drugs used as first salvage treatment for Hodgkin’s lymphoma that has returned or not responded to previous treatments.

Study of Nivolumab for Early Stage Hodgkin Lymphoma in Patients with Good Prognosis

This study is for early-stage Hodgkin lymphoma patients with good prognosis. Eligible patients must be between 18 and 70 years old with confirmed classical Hodgkin lymphoma at Stage I or II A without large tumors. They must not have received prior treatment and have an ECOG performance status of 0-2. Patients need adequate organ function, including liver enzymes and bilirubin less than specified limits, hemoglobin greater than 8 g/dL, neutrophil count of at least 1,000 per microliter, and platelet count of at least 100,000 per microliter. Women of childbearing potential must have negative pregnancy tests and agree to use two effective birth control methods.

Excluded patients include those with bulky lesions, constitutional symptoms (fever, night sweats, weight loss), high metabolic tumor volume, positive interim PET scan after 2 ABVD cycles, disease not in early stage I-IIA, or not considered low-risk.

The trial explores whether chemotherapy alone without radiation can effectively treat patients with good prognosis. It investigates using Nivolumab for patients at higher risk of progression who don’t respond well to initial treatment. The study monitors patients’ progress over time to assess the treatment’s safety and effectiveness.

Investigational drugs: ABVD is a chemotherapy regimen used for early-stage Hodgkin lymphoma to determine if it can effectively treat patients without radiation therapy, especially those with good prognosis.

Study of Pembrolizumab with Chemotherapy for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

This trial is for patients with classical Hodgkin lymphoma experiencing first relapse or primary refractory disease. Participants must be 18-65 years old with no previous treatment for relapsed or refractory disease. They must have written informed consent, life expectancy over 3 months, negative pregnancy test for women, and measurable disease with lesions that can be measured. ECOG performance status must be 0-1, and patients must be eligible for autologous stem cell transplantation as determined by the investigator.

Patients who have not experienced first relapse or are not primary refractory to classical Hodgkin lymphoma cannot participate.

The study tests pembrolizumab (anti-PD-1 antibody) combined with chemotherapy regimens including ICE (ifosfamide, carboplatin, etoposide) and DHAP (dexamethasone, high-dose cytarabine, cisplatin). Participants receive four cycles of combination therapy, followed by restaging and potential high-dose chemotherapy with autologous stem cell transplantation. The trial monitors response to treatment, overall survival, and quality of life.

Investigational drugs: Pembrolizumab helps the immune system recognize and attack cancer cells. ICE Chemotherapy combines three drugs that work together to kill or stop cancer cell growth. DHAP Chemotherapy is another combination that attacks cancer cells and prevents their multiplication.

Study of Pembrolizumab with Hyaluronidase for Patients with Relapsed or Refractory Hodgkin Lymphoma or Primary Mediastinal Large B-cell Lymphoma

This study is for patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma. Eligible participants must have confirmed diagnosis, measurable disease using imaging tests, life expectancy of at least three months, well-controlled HIV if infected, and ECOG performance status of 0-1. Patients with hepatitis B must be on antiviral medication for at least four weeks with no detectable virus. Those with hepatitis C history must have completed treatment at least four weeks before the study with no detectable virus at screening.

Excluded patients include those with other cancer types, previous severe allergic reactions to similar treatments, active infections requiring treatment, pregnancy or breastfeeding, certain unstable heart conditions, recent participation in another trial, history of certain autoimmune diseases, recent major surgery, uncontrolled high blood pressure, or history of substance abuse.

The trial uses MK-3475A, a solution containing pembrolizumab combined with hyaluronidase. Pembrolizumab helps the immune system fight cancer cells by blocking a protein that prevents immune attack. Hyaluronidase helps improve medication absorption when injected under the skin. Participants receive treatment in cycles for up to 24 months, with regular monitoring of response and side effects.

Investigational drugs: Pembrolizumab is immunotherapy that helps the immune system recognize and attack cancer cells more effectively. Hyaluronidase is an enzyme that temporarily breaks down hyaluronic acid to help medication spread more easily and be absorbed more effectively when injected under the skin.

Study of Ruxolitinib with Brentuximab or Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

This trial is for patients with classical Hodgkin lymphoma that has returned or not responded to treatments. Participants must be 18 years or older with relapsed or refractory disease. For Cohort-1 (ruxolitinib with brentuximab), patients must have CD30+ disease after autologous stem cell transplantation or at least two previous treatments if transplant is not suitable. They cannot have received allotransplant previously and must be able to receive at least 8 brentuximab infusions. For Cohort-2 (ruxolitinib with pembrolizumab), patients must have relapsed or refractory disease previously treated with transplant or at least two prior therapies when transplant is not an option, and cannot have received PD1 or PDL1 inhibitors.

Patients are excluded if they only had partial response to last treatment, showed no improvement or worsening after last treatment, or had partial response to salvage therapy before transplant unless condition worsens later.

The study tests ruxolitinib combined with either brentuximab vedotin or pembrolizumab. Ruxolitinib works by inhibiting proteins that help cancer cells grow and survive. Brentuximab is an antibody-drug conjugate that targets and destroys cancer cells. Pembrolizumab is immunotherapy that helps the immune system fight cancer. The trial aims to improve complete response rates and assess effectiveness before stem cell transplants.

Investigational drugs: Ruxolitinib inhibits JAK1/2 proteins involved in cancer cell growth. Brentuximab targets CD30 protein on cancer cells and delivers toxic substance to kill them. Pembrolizumab blocks a protein that prevents immune system from attacking cancer cells, allowing better recognition and destruction.

Study of Tislelizumab, Dacarbazine, Vinblastine Sulfate, and Doxorubicin Hydrochloride for Adults with Early-Stage Unfavorable Hodgkin Lymphoma

This trial is for early-stage unfavorable classical Hodgkin lymphoma patients. Eligible participants must be 18-60 years old (or 61+ for exploratory group) with first diagnosis confirmed by tissue sample. For the exploratory group, participants must be eligible for 4 cycles of AVD chemotherapy with total CIRS-G score less than 10 and score 3 or less for each organ system. Patients must have early-stage unfavorable disease with no previous treatment except corticosteroids if needed. They must be able to provide consent, follow study requirements, have life expectancy over 3 months, and adequate organ function. Women of childbearing potential must use effective birth control and have negative pregnancy test. Men must use barrier methods for birth control.

Excluded patients include those with different cancer type, outside specified age range, pregnant or breastfeeding, uncontrolled serious infection, history of another cancer within 5 years (with certain exceptions), autoimmune disease, recent live vaccine, known allergy to study drugs, or uncontrolled heart, lung, liver, or kidney disease, or currently in another clinical trial.

The study tests tislelizumab (immunotherapy) combined with dacarbazine, vinblastine sulfate, and doxorubicin hydrochloride. Treatment is guided by PET scans to assess cancer response. The trial aims to find a personalized treatment option that may improve outcomes and quality of life by determining whether adding tislelizumab can improve progression-free survival for at least one year.

Investigational drugs: Tislelizumab is a checkpoint inhibitor that helps the immune system recognize and attack cancer cells more effectively by blocking a protein that prevents immune recognition of cancer.

Study of Tislelizumab, Gemcitabine, and Cisplatin for Patients with Relapsed or Refractory Hodgkin Lymphoma in Metabolic Complete Remission

This study is for patients with Hodgkin lymphoma that has returned or not responded to treatment. Participants must have confirmed classical Hodgkin lymphoma, be able to attend study visits, and have negative pregnancy test if female. Women of childbearing potential must use two effective birth control methods or abstain from intercourse during the study and for 6 months after. Men must use effective barrier contraception or abstain during the study and for 6 months after. Patients must have primary refractory disease or first relapse after previous chemotherapy, with relapse confirmed by biopsy or imaging. They must have measurable disease on CT scan, be 18-70 years old, have WHO/ECOG Performance Status 0-1, hemoglobin greater than 8 g/dL, neutrophil count at least 1,000 per microliter, platelet count at least 100,000 per microliter, adequate organ function, and resolved previous treatment side effects.

Excluded patients include those with other serious health conditions, pregnancy or breastfeeding, another cancer within 5 years (except certain skin cancers), active infection requiring treatment, recent live vaccine, organ transplant, allergy to study drugs, history of autoimmune disease, or uncontrolled high blood pressure, heart disease, or substance abuse within last year.

The trial tests tislelizumab (immune checkpoint inhibitor) combined with gemcitabine and cisplatin chemotherapy. Patients receive this combination initially, followed by additional tislelizumab if they achieve complete remission. The study evaluates whether this approach can help prevent cancer recurrence or worsening over two years.

Investigational drugs: Tislelizumab helps the immune system recognize and attack cancer cells by blocking PD-1 protein. Gemcitabine stops cancer cell growth by interfering with DNA replication. Cisplatin kills cancer cells by damaging their DNA and preventing division.

Study on Preventing Hypothyroidism in Patients with Medulloblastoma and Pediatric Lymphoma Using Levothyroxine During Radiation Therapy

This study focuses on preventing hypothyroidism (when the thyroid doesn’t produce enough hormones) in patients with medulloblastoma, Hodgkin lymphoma, and non-Hodgkin lymphoma receiving radiation therapy near the thyroid gland. Eligible patients must have one of these conditions and be in the stage before starting radiotherapy that includes the thyroid area. They must not have had previous primary or secondary hypothyroidism and must provide written informed consent. The study is open to male and female patients of various age groups including children, adolescents, and adults.

Excluded patients include those not diagnosed with these specific conditions or outside the specified age range. Gender is not a reason for exclusion, and the study is open to vulnerable populations.

The trial tests whether levothyroxine can reduce hypothyroidism risk after radiation therapy. Some patients receive levothyroxine during radiation while others don’t, to compare results. Participants are monitored for three years after radiation to check for hypothyroidism signs. The study aims to find better ways to manage cancer treatment side effects and improve quality of life.

Investigational drugs: Levothyroxine is used to help protect the thyroid gland during radiation therapy. It works by suppressing thyroid-stimulating hormone production, which may help reduce hypothyroidism risk in patients receiving radiation for medulloblastoma, Hodgkin lymphoma, and non-Hodgkin lymphoma.

Study on the Effectiveness and Safety of Tislelizumab for Patients with Newly Diagnosed Hodgkin Lymphoma Who Cannot Have Standard Chemotherapy

This trial is for patients with newly diagnosed classical Hodgkin lymphoma who cannot undergo standard chemotherapy. Participants must have confirmed diagnosis, be able to attend study visits and follow requirements, and be 65 years or older and unsuitable for standard chemotherapy due to medical conditions. They must not have received previous treatment, have measurable disease, and need whole-body treatment except certain early-stage cases where radiation alone can cure. ECOG performance status must be 2 or less, with adequate organ and marrow function including specific blood counts and kidney and liver function tests. Life expectancy must be at least 6 months, and men must agree to use effective birth control from consent until 4 months after last dose.

Excluded patients include those who received previous treatment, are suitable for chemotherapy, or are part of vulnerable populations.

The study uses tislelizumab, a solution given through intravenous infusion. Tislelizumab helps the immune system fight cancer cells by blocking the PD-1 protein. The trial evaluates overall response rate, including complete and partial responses, over up to 24 months. It also monitors duration of response, progression-free survival, overall survival, and side effects.

Investigational drugs: Tislelizumab is immunotherapy that helps the immune system recognize and attack cancer cells by blocking PD-1 protein on immune cell surfaces, making it easier for immune system to detect and destroy cancer.

Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

This study is for patients with advanced stage classic Hodgkin lymphoma. Eligible participants must have confirmed first diagnosis at Stage III or IV, or Stage IIB with large chest mass or disease outside lymph nodes. They must be 18-60 years old, willing to provide written consent, and have adequate blood test results including hemoglobin at least 8 g/dL without recent transfusion, white blood cell count at least 3 x 109/L, platelet count at least 100 x 109/L without recent transfusion, and neutrophil count at least 1.0 x 109/L. ECOG score must be 0 or 1 (able to perform daily activities with minimal assistance), and life expectancy must be greater than 3 months. Women of childbearing potential must not be pregnant or breastfeeding and agree to use effective contraception during study and for 6 months after. Men must agree to use contraception during study and for 6 months after, and not donate sperm during this period.

Excluded patients include those below 18 or above 60 years old, with previous Hodgkin lymphoma treatment, active infections, pregnancy or breastfeeding, history of another cancer in past 5 years, severe heart conditions, uncontrolled heart disease, severe liver or kidney problems, active autoimmune disease, known allergy to study medications, mental conditions interfering with study procedures, participation in another trial within 30 days, use of interfering medications, HIV infection, or active hepatitis B or C.

The trial tests pembrolizumab (Keytruda) combined with P-BrECADD regimen. Treatment includes one pembrolizumab dose followed by 4-6 cycles of combination therapy. Some patients may receive radiation therapy as standard care. The study monitors response using PET scans and tracks health status for at least one year after treatment.

Investigational drugs: Pembrolizumab is immunotherapy that helps immune system recognize and attack cancer cells by blocking PD-1 protein. P-BrECADD is combination chemotherapy containing multiple medications that attack cancer cells in various ways to make treatment more effective.

Summary

This overview presents 27 ongoing clinical trials investigating treatments for Hodgkin’s disease across Europe. The trials span multiple countries, with notable concentrations in France, Germany, Italy, and Spain. Several trials are also being conducted in Belgium, the Netherlands, Poland, and the Czech Republic.

A common focus among these studies is the investigation of immunotherapy approaches, particularly pembrolizumab and nivolumab, often combined with traditional chemotherapy regimens. Several trials specifically test brentuximab vedotin, both as a standalone treatment and in various combinations with other medications. Many studies are designed for patients with relapsed or refractory disease, though some focus on newly diagnosed patients.

The trials encompass various disease stages, from early-stage favorable prognosis cases to advanced-stage disease. Several studies use PET scan-guided treatment approaches to personalize therapy based on individual response. A significant number of trials are investigating whether newer treatment combinations can reduce side effects while maintaining or improving effectiveness compared to standard therapies.

Several trials include pediatric and young adult populations, addressing the specific needs of these age groups. Some studies explore preventing treatment-related complications, such as hypothyroidism following radiation therapy. The concentration of trials testing immunotherapy combinations reflects current research trends in improving outcomes while reducing treatment toxicity.

Ongoing Clinical Trials on Hodgkin’s disease

  • Study on Preventing Hypothyroidism in Patients with Medulloblastoma and Pediatric Lymphoma Using Levothyroxine During Radiation Therapy

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Safety of HSP-CAR30 Immunotherapy for Patients with Relapsed or Refractory CD30+ Hodgkin and Non-Hodgkin Lymphoma

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Triptorelin for Fertility Protection in Young Women and Teenagers Undergoing Chemotherapy for Breast Cancer, Leukemia, Lymphomas, and Sarcomas

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study of Tislelizumab, Gemcitabine, and Cisplatin for Patients with Relapsed or Refractory Hodgkin Lymphoma in Metabolic Complete Remission

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark The Netherlands

  • Study on Early Response to Brentuximab Vedotin and Drug Combination for Advanced Hodgkin Lymphoma Patients

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark The Netherlands Poland Portugal Slovakia +1

More information about
Hodgkin’s disease:

Connected medications: